Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease - the BOOGIE Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.

Who May Be Eligible (Plain English)

Who May Qualify: - diagnosis of inflammatory rheumatic joint disease - indication of disease modifying treatment initiation with or without glucocorticoids OR - stable DMARD treatment with parenteral glucocorticoid injection Who Should NOT Join This Trial: - known osteoporosis or osteoporosis treatment - women during the transitory phase - oestrogen treatment - any fracture within the last year - chronic glucocorticoid treatment - glucocorticoid treatment within the last year prior to inclusion - active cancer - kidney failure Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * diagnosis of inflammatory rheumatic joint disease * indication of disease modifying treatment initiation with or without glucocorticoids OR * stable DMARD treatment with parenteral glucocorticoid injection Exclusion Criteria: * known osteoporosis or osteoporosis treatment * women during the transitory phase * oestrogen treatment * any fracture within the last year * chronic glucocorticoid treatment * glucocorticoid treatment within the last year prior to inclusion * active cancer * kidney failure

Treatments Being Tested

DRUG

Glucocorticoid Effect

Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.

Locations (2)

Vestre Viken HF, Drammen
Drammen, Norway
Diakonhjemmet hospital
Oslo, Norway